Randomized, placebo-controlled pilot trial of the effects of α-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients Journal Article
| Authors: | Mahabir, S.; Frenkel, K.; Brady, M. S.; Coit, D.; Leibes, L.; Karkoszka, J.; Berwick, M. |
| Article Title: | Randomized, placebo-controlled pilot trial of the effects of α-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients |
| Abstract: | We conducted a randomized, placebo-controlled pilot trial to assess whether supplementation of 1000 mg/day α-tocopherol for 3 months offered protection against DNA base damage in melanoma outpatients (n=46). Plasma autoantibodies (aAbs) against 5-hydroxymethyl-2-deoxyuridine (HMdU) were measured as an immune marker of DNA base damage. After 3 months of supplementation (final level), plasma levels of α-tocopherol increased significantly (P<0.0005) in the α-tocopherol compared with the placebo treatment group. Supplementation with α-tocopherol also resulted in a significant (P=0.04) decrease in plasma γ-tocopherol levels among males. Overall, we did not find any significant differences in the plasma anti-HMdU aAb levels between the two treatment groups. However, when the patients were stratified by the clinical characteristics of the melanoma, we found that α-tocopherol supplementation resulted in a borderline significant (P=0.06) 48% decrease in plasma anti-HMdU aAb levels in patients with less aggressive melanomas (Breslow thickness ≤ 1 mm) only. Within-group analysis showed that women had significantly (P<0.05) higher baseline levels of anti-HMdU aAbs compared with men in each treatment group. However, the final levels of anti-HMdU aAbs were significantly (P<0.05) higher in women in the α-tocopherol supplemented group only. Although reliable conclusions cannot be drawn from this pilot study, which is limited by the small sample size, the results suggest that short-term α-tocopherol supplementation may offer some protection against less aggressive melanomas. Further studies using much larger sample sizes are required to confirm this finding. © 2004 Lippincott Williams & Wilkins. |
| Keywords: | adult; clinical article; controlled study; middle aged; clinical trial; cigarette smoking; placebo; antineoplastic agents; dna damage; dna repair; melanoma; controlled clinical trial; skin neoplasms; randomized controlled trial; enzyme linked immunosorbent assay; diet supplementation; dna; pilot projects; antioxidants; dietary supplements; alpha tocopherol; autoantibody; antibody detection; double blind procedure; double-blind method; autoantibodies; thymidine; placebos; supplementation; vitamin blood level; vitamin e; vitamin intake; alpha-tocopherol; humans; human; male; female; priority journal; article; α-tocopherol; 5-hydroxymethyl-2-deoxyuridine; anti-hmdu antibodies; 5 hydroxymethyldeoxyuridine; gamma-tocopherol |
| Journal Title: | Melanoma Research |
| Volume: | 14 |
| Issue: | 1 |
| ISSN: | 0960-8931 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2004-01-01 |
| Start Page: | 49 |
| End Page: | 56 |
| Language: | English |
| PROVIDER: | scopus |
| DOI: | 10.1097/01.cmr.0000113342.53882.3d |
| DOI/URL: | |
| Notes: | Melanoma Res. -- Cited By (since 1996):4 -- Export Date: 16 June 2014 -- CODEN: MREEE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work